NCT03142334, Pembrolizumab, renal cell carcinoma

Pembrolizumab inotenderwa kurapa adjuvant renal cell carcinoma

Jan 2022: Pembrolizumab (Keytruda, Merck) yakatenderwa neFood and Drug Administration yekurapa adjuvant yevarwere vane renal cell carcinoma (RCC) vari pakati-yakakwirira kana yakanyanya njodzi yekudzokororwa mushure me…

KEYTRUDA, Lenvatinib, Lenvatinib pamwe pembrolizumab, Lenvima, Merck, renal cell carcinoma

Iyo FDA yakabvumidza kusangana kwelenvatinib uye pembrolizumab yepamberi renal cell carcinoma

Nyamavhuvhu 2021: Iko kusanganiswa kwelenvatinib (Lenvima, Eisai) uye pembrolizumab (Keytruda, Merck) yakagamuchirwa neKudya neDrug Administration kwekutanga-kurapwa kurapwa kwevakuru varwere vane yepamusoro renal cell carcinom ..

AVEO Mishonga, Fotivda, kinase inhibitor, Refractory yemhando yepamusoro renal cell carcinoma, renal cell carcinoma, tivozanib

Tivozanib yakagamuchirwa neDFA yekurapwa kwekudzokazve kana kukanganisa kweiyo renal cell carcinoma.

Nyamavhuvhu 2021: Tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), kinase inhibitor, yakagamuchirwa neDFA kune vakuru varwere vane yakadzokororwa kana yekuratidzira yepamusoro renal cell carcinoma (RCC) mushure memaviri kana kupfuura apfuura systemic iyo ..

8 honzeri huru dzekenza yeitsvo

Many patients with kidney cancer do not know why they have this disease, meaning the causes of kidney cancer are relatively unknown. After the examination, they will be very surprised. Some even feel that the kidney is not a probl..